
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
View the Pharmaceutical Executive August 2025 issue in an interactive format.
Click
about 1 year ago
The CAR-T Climbabout 1 year ago
2025 Emerging Pharma Leadersabout 1 year ago
An RNA-Guided Pathabout 1 year ago
Acceleration and Ambitionabout 1 year ago
Driving Disruption in Deliveryabout 1 year ago
Building Promise from Precisionabout 1 year ago
Determined Problem-Solverover 1 year ago
Direct-to-Consumer Prescription Care Comes of Ageover 1 year ago
How to Get Product Iteration Right in Healthcare





